| Popis: |
Peripheral blood progenitor cells (PBPC), mobilised by several and collected in apheresis procedures are able to restore hemopoiesis after myeloablative, intensive chemotherapy. This has been currently used in the treatment of several solid tumours as well as haematological neoplasias. Several studies have show tha a safe threshold of PBPS, measured as CD34+ cells, in order to produce a prompt and durable engraftment of autologous marrow is that of 5 × 106 CD34+ cells/kg recipient body weight. Values below lead to a risk for delayed peripheral blood count recovery or even engraftment failure [1]. Many factors affect the number of CD34+ cells after mobilisation procedures, such as time from diagnosis to mobilisation, amount of previous chemotherapy regimens received by the patients, specially the cumulative dosis of alkylating agents and fludarabine [2, 3, 4, 5, 6]. |
